Pilot program by IU and Davos Alzheimer’s Collaborative to test AI-powered cognitive screening at scale

How AI, Dig­i­tal Screen­ing Tools Can Help Flag Ear­ly Cog­ni­tive Decline (Health IT Ana­lyt­ics): Ear­ly diag­no­sis of Alzheimer’s and oth­er demen­tias remains at the fore­front of efforts to min­i­mize the impact of these neu­rode­gen­er­a­tive dis­eases. But chal­lenges such as increased life expectan­cy and the risks of aging, along with com­plex­i­ties in diag­no­sis and treat­ment resulting…

Read More

Precision psychiatry pioneer Alto Neuroscience raises $35M to advance digital biomarker-to-treatment platform

Alto Neu­ro­science Rais­es $35M Series B Financ­ing (Fins­Mes): Alto Neu­ro­science, a Los Altos, CA-based neu­ro-tech com­pa­ny which spe­cial­izes in pre­ci­sion psy­chi­a­try, rais­es $35M Series B Financ­ing … The com­pa­ny intends to use the funds to advance lead can­di­dates into Phase 2b stud­ies in major depres­sive dis­or­der … Pro­ceeds from the financ­ing will also be used…

Read More

AI-enabled chatbot Wysa receives FDA Breakthrough Device designation for patients with chronic pain, depression and anxiety

AI Behav­ior Health Chat­bot App Fast-Tracked by FDA (Psy­chol­o­gy Today): Recent­ly the U.S. Food and Drug Admin­is­tra­tion (FDA) grant­ed break­through device des­ig­na­tion to Wysa’s AI-based dig­i­tal men­tal health con­ver­sa­tion­al agent that deliv­ers cog­ni­tive behav­ioral ther­a­py (CBT) via a smart­phone to adults suf­fer­ing from depres­sion, anx­i­ety, and chron­ic mus­cu­loskele­tal pain

Read More

Geisinger and Eisai to test real-world validity of AI-powered Passive Digital Marker (PDM) in detecting early cognitive impairment and dementia

Research col­lab­o­ra­tion will test nov­el algorithm’s effec­tive­ness on Geisinger data (press release): Geisinger and Eisai Inc. today announced a col­lab­o­ra­tive effort to study the poten­tial effec­tive­ness of an arti­fi­cial intel­li­gence (AI) tool in the detec­tion of cog­ni­tive impair­ment that could iden­ti­fy demen­tias, includ­ing Alzheimer’s dis­ease (AD). If effec­tive, the AI tool could poten­tial­ly be developed…

Read More

Mapping ‘psychedelic trips’ in the brain to better direct their therapeutic effects

For the past sev­er­al decades, psy­che­delics have been wide­ly stig­ma­tized as dan­ger­ous ille­gal drugs. But a recent surge of aca­d­e­m­ic research into their use to treat psy­chi­atric con­di­tions is spurring a recent shift in pub­lic opin­ion. Psy­che­delics are psy­chotrop­ic drugs: sub­stances that affect your men­tal state. Oth­er types of psy­chotrop­ics include anti­de­pres­sants and anti-anx­i­e­ty medications.…

Read More

Beacon Biosignals raises $27M to scale EEG, AI-based neurobiomarker discovery platform

Neu­rotech start­up Bea­con Biosig­nals scores $27M to bring AI to EEG analy­sis (Med­C­i­ty News): Elec­troen­cephalog­ra­phy is a decades-old tech­nique for cap­tur­ing brain activ­i­ty, data that are used to eval­u­ate brain dis­or­ders. Bea­con Biosig­nals is apply­ing arti­fi­cial intel­li­gence to these tests, and the neu­rotech­nol­o­gy start­up has found a ready mar­ket in phar­ma­ceu­ti­cal com­pa­nies inter­est­ed in assess­ing how…

Read More